Biological Activity
GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis[1].
In Vitro
GLPG2938 (0.5~5 μM; HPF cells) significantly prevents the S1P-mediated contraction at all tested concentrations[1].
In Vivo
GLPG2938 (1~10 mg/kg; p.o.) displays a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score[1]. GLPG2938 shows good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs[1]. Animal Model: Male C57BL/6 mice[1] Dosage: 1~10 mg/kg Administration: P.o. Result: Displayed a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score.
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
